calorie intake on semaglutide Semaglutide: Optimal Range Wondering how everyone is losing

Pozzi, M

Fiber supplements can assist if you confront constipation

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes

In the context of Retatrutide research, GCGR activation is studied primarily for its energy expenditure effects particularly increased thermogenesis and hepatic fat oxidation which add a distinct and significant metabolic dimension to the GLP-1R and GIPR incretin effects already present in dual agonists like Tirzepatide

These weight loss and diabetes meds are raising hopes and questions in the bipolar community

Stanford Magazine